Official Title: Safety and Efficacy Evaluation Study of FYU-981 Long-term Administration for Hyperuricemia With or Without Gout (Phase III Study)
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Dotinurad (Primary)
- Indications Gout; Hyperuricaemia
- Focus Registrational; Therapeutic Use
- Sponsors Fuji Yakuhin
- 04 Dec 2018 Status changed from active, no longer recruiting to completed.
- 07 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 03 Jan 2017 New trial record